# Study to Evaluate the Efficacy and Safety of Tacrolimus in Kidney Transplant Recipients (BLOSSOM)

> **NCT04224350** · PHASE4 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 184 (estimated)

## Conditions studied

- Kidney Transplant

## Interventions

- **DRUG:** TacroBell SR cap.
- **DRUG:** Tacrolimus cap.

## Key facts

- **NCT ID:** NCT04224350
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-17
- **Primary completion:** 2020-07-30
- **Final completion:** 2020-11-30
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2020-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04224350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04224350, "Study to Evaluate the Efficacy and Safety of Tacrolimus in Kidney Transplant Recipients (BLOSSOM)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04224350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*